Article info
PDFClinical and epidemiological research
Extended report
Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA)
- Correspondence to Dr Jens Klotsche, German Rheumatism Research Centre, a Leibniz Institute, Chariteplatz 1, Berlin 10117, Germany; Jens.Klotsche{at}drfz.de
Citation
Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA)
Publication history
- Received October 7, 2014
- Revised December 16, 2014
- Accepted April 5, 2015
- First published April 29, 2015.
Online issue publication
April 26, 2021
Article Versions
- Previous version (26 April 2021).
- Previous version (26 April 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/